Pharmather Hldgs Ltd (PHRRF)

$0.34 -0.02 (-4.47%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 205,500
Avg Vol 351,926
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 22%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 888-846-3171
Address:
82 Richmond Street East, Toronto, Canada
Joeyboy12
Joeyboy12 Jul. 16 at 4:08 PM
$PHRRF to help stay in the loop for approval https://www.rttnews.com/corpinfo/fdacalendar.aspx?PageNum=5
0 · Reply
Johnm_
Johnm_ Jul. 16 at 11:50 AM
$PHRRF 100% Buy https://barchart.com/stocks/quotes/phrrf
0 · Reply
John_morris
John_morris Jul. 15 at 11:39 PM
$PHRRF Word of the day - VOLUME
0 · Reply
Moneymaknmarsh
Moneymaknmarsh Jul. 14 at 6:34 PM
$PHRRF Good Luck Making Money
1 · Reply
Johnm_
Johnm_ Jul. 14 at 2:41 PM
$PHRRF
0 · Reply
Johnm_
Johnm_ Jul. 14 at 11:36 AM
$PHRRF loading zone strong buy!!
0 · Reply
Johnm_
Johnm_ Jul. 14 at 9:48 AM
$PHRRF - Strong buy
0 · Reply
Johnm_
Johnm_ Jul. 14 at 9:05 AM
$PHRRF PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine https://www.pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf https://finance.yahoo.com/news/pharmather-announces-path-ketamine-commercialization-120000030.html
0 · Reply
QES
QES Jul. 13 at 9:21 PM
$PHRRF 1/2 I asked AI How Soon Could PharmaTher File for International Registration After FDA Approval? PharmaTher has stated its intent to pursue international registrations for KetaRX in key markets such as Europe, the UK, Canada, Japan, and the Asia-Pacific region after receiving FDA approval in the U.S. The timing of these filings is a critical question for investors and stakeholders. Potential Speed of International Filings No Explicit Waiting Period: There is no regulatory requirement that would prevent PharmaTher from filing for international approvals immediately after receiving FDA approval. In fact, companies often prepare documentation in parallel to expedite global submissions. Company Preparedness: PharmaTher has emphasized its readiness for commercialization and has previously indicated that international submissions would begin in the second half of 2025, following U.S. approval.
1 · Reply
John_morris
John_morris Jul. 10 at 10:25 PM
$PHRRF https://www.youtube.com/watch?v=6aVtN0Oc1CI PHRRF at 7.50 minute mark
0 · Reply
Latest News on PHRRF
No data available.
Joeyboy12
Joeyboy12 Jul. 16 at 4:08 PM
$PHRRF to help stay in the loop for approval https://www.rttnews.com/corpinfo/fdacalendar.aspx?PageNum=5
0 · Reply
Johnm_
Johnm_ Jul. 16 at 11:50 AM
$PHRRF 100% Buy https://barchart.com/stocks/quotes/phrrf
0 · Reply
John_morris
John_morris Jul. 15 at 11:39 PM
$PHRRF Word of the day - VOLUME
0 · Reply
Moneymaknmarsh
Moneymaknmarsh Jul. 14 at 6:34 PM
$PHRRF Good Luck Making Money
1 · Reply
Johnm_
Johnm_ Jul. 14 at 2:41 PM
$PHRRF
0 · Reply
Johnm_
Johnm_ Jul. 14 at 11:36 AM
$PHRRF loading zone strong buy!!
0 · Reply
Johnm_
Johnm_ Jul. 14 at 9:48 AM
$PHRRF - Strong buy
0 · Reply
Johnm_
Johnm_ Jul. 14 at 9:05 AM
$PHRRF PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine https://www.pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf https://finance.yahoo.com/news/pharmather-announces-path-ketamine-commercialization-120000030.html
0 · Reply
QES
QES Jul. 13 at 9:21 PM
$PHRRF 1/2 I asked AI How Soon Could PharmaTher File for International Registration After FDA Approval? PharmaTher has stated its intent to pursue international registrations for KetaRX in key markets such as Europe, the UK, Canada, Japan, and the Asia-Pacific region after receiving FDA approval in the U.S. The timing of these filings is a critical question for investors and stakeholders. Potential Speed of International Filings No Explicit Waiting Period: There is no regulatory requirement that would prevent PharmaTher from filing for international approvals immediately after receiving FDA approval. In fact, companies often prepare documentation in parallel to expedite global submissions. Company Preparedness: PharmaTher has emphasized its readiness for commercialization and has previously indicated that international submissions would begin in the second half of 2025, following U.S. approval.
1 · Reply
John_morris
John_morris Jul. 10 at 10:25 PM
$PHRRF https://www.youtube.com/watch?v=6aVtN0Oc1CI PHRRF at 7.50 minute mark
0 · Reply
John_morris
John_morris Jul. 10 at 8:36 PM
$PHRRF Some Volume during the last 2 days and Green - No complaints. Looking ahead to the next 2 weeks and expecting a steady climb in pps.
0 · Reply
QES
QES Jul. 10 at 12:19 AM
$PHRRF Regarding competition for KetaRX, there is only one other near it, NRx Pharma, which expects a decision by year-end 2025. Their selling point appears to be that their product, NRX-100, is preservative-free, eliminating benzethonium chloride, a preservative linked to toxicity concerns in traditional ketamine formulations. NRx intends to file a citizen's petition with the FDA to remove benzethonium chloride from IV ketamine. Thing is, AI states that KetaRX is likely preservative-free and does not contain benzethonium chloride, based on current disclosures and market positioning.
0 · Reply
QES
QES Jul. 9 at 1:38 AM
$PHRRF Fabio Chianelli owns approximately 15.5 million shares of PharmaTher Holdings. This represents about 17.5% to 18.7% of the company’s outstanding shares, making him by far the largest individual shareholder. That matters! His interests match ours.
0 · Reply
QES
QES Jul. 9 at 1:31 AM
$PHRRF My attention now is on what to do if and when approval is granted. There is a lot to consider. The company is preparing regulatory submissions for: Europe (European Medicines Agency, EMA) United Kingdom Canada Japan Asia-Pacific (APAC) regions They have Orphan Drug status for these, giving them 7 years exclusive marketing: Rett Syndrome Granted Yes Complex Regional Pain Syndrome Granted Yes Amyotrophic Lateral Sclerosis Granted Yes Status Epilepticus Granted Yes Ischemia-reperfusion injury (transplant) Granted Yes
2 · Reply
QES
QES Jul. 9 at 1:14 AM
$PHRRF ProKidney's stock surged over 422 percent recently due to the release of positive topline results from its Phase 2 REGEN-007 clinical trial for its lead therapy, rilparencel, targeting chronic kidney disease (CKD) and diabetes. That's just a phase 2 study, far from FDA approval. Risk is still high there. For PHRRF, we are expecting an FDA approval, and that is a game changer. A company with no revenue, a current market cap of less that $30 million, and all risk gone, makes this a big deal. AI says that the probability of approval is "Very High (>90%)" for drugs like this. AND "Statistically, minor amendments almost always lead to registration, provided the applicant addresses the FDA’s requests. The process is designed to resolve minor issues and move the application toward approval efficiently"
1 · Reply
John_morris
John_morris Jul. 8 at 7:58 PM
$PHRRF Just a thought - - Not sure how many options were exercised in exchange for shares and then what % of those shares were sold during the pps run - into the high .30s during the last week or two. A good way to make some easy and really nice profit (% wise - close to 200%- 300% profit, given the low strike prices - - - 0.1, 0.15, 0.16, 0.18) See the expiry dates on these options and the respective strike prices ( at the current pps all but one strike price of .91 that expires in Sept.2026 can be exercised and converted into shares). Note: These are in addition to the 16.8M warrants that have a strike price of .80 that expire in Sept.2026
1 · Reply
QES
QES Jul. 8 at 5:54 PM
$PHRRF Watching the action of PROK (ProKidney) today, which was a $177 mil market cap company (60 cents at close yesterday) yesterday, and is now $4.17 a share, is encouraging for us here in PharmaTher. PHRRF's market cap is much less, and hopefully we'll see something spectacular in a month.
1 · Reply
John_morris
John_morris Jul. 8 at 3:16 PM
$PHRRF Need Volume to make a comeback. One month to go for approval. Hopefully, no nasty surprises this time.
0 · Reply
Johnm_
Johnm_ Jul. 7 at 4:18 PM
$PHRRF - PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine https://finance.yahoo.com/news/pharmather-announces-path-ketamine-commercialization-120000030.html
0 · Reply
Johnm_
Johnm_ Jul. 2 at 3:53 PM
$PHRRF
0 · Reply
John_morris
John_morris Jul. 2 at 2:37 PM
$PHRRF FWIW Just got the invite! Looking forward to it. A BIG THANK YOU to the FDA for listening to Pharma and Biotech CEOs! Psychedelics and, of course, Ketamine will be on my agenda. CEO Forums: An FDA Listening Tour to Engage Pharma and Bio CEOs – New York, NY – July 30, 2025 https://x.com/FabioChianelli/status/1940412931050553528
2 · Reply
John_morris
John_morris Jul. 2 at 12:38 PM
$PHRRF Lack of confidence or something else - why a PR with no meat in it ? PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine https://www.pharmather.com/news/pharmather-announces-path-to-ketamine-commercialization-with-no-planned-financing-confirms-fda-approval-goal-date-of-august-9th-2025-for-ketamine
1 · Reply